MIT Researcher Allegedly Copied Other Groups’ Drug Designs

Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, MTCURADO

MIT biological engineer Ram Sasisekharan may have copied other researchers’ designs for antibody therapies and passed them off as his own, according to researchers at Adimab, a New Hampshire–based private firm focused on antibody discovery. Outlining the allegations in a paper published last week (May 20) in mAbs, the company claims that at least two monoclonal antibody drugs in development—one against Zika and the other against influenza—described by Sasisekharan’s lab bear strong resemblances to already published work.

“We assembled the facts, we checked the facts with the leading antibody experts outside of Adimab and they all agreed with us,” paper coauthor Tillman Gerngross, Adimab’s CEO, tells Endpoints News. “If you look at the facts it looks like serious misconduct.”

Sasisekharan’s lab focuses on the use of computer algorithms to discover and develop new drugs—an approach that has helped him launch three biotechs and attract considerable investor ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Catherine Offord

    Catherine is a science journalist based in Barcelona.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio